Company intelligence / Profile preview
United Therapeutics Corporation
Silver Spring, Maryland, USAunither.com ↗
- Ownership
- Public · UTHR
- Employees
- ~1237
- Development stage
- Other
01
Overview
United Therapeutics is a leading biotechnology company focused on rare diseases and end-stage organ disease. It has several FDA-approved products for PAH and PH‑ILD, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin. The company is advancing late-stage clinical trials in fibrotic lung diseases and pioneering organ manufacturing/xenotransplantation platforms. Recent clinical results include positive outcomes for Tyvaso DPI in PH‑ILD and ongoing pivotal studies in idiopathic pulmonary fibrosis.[1][2][8][10]
- Therapeutic areas
- OncologyPulmonologyCardiovascular
- Modalities
- Small molecules (e.g., treprostinil, tadalafil)Monoclonal antibodies (e.g., dinutuximab)Cell-based therapiesOrgan bioengineering/xenotransplantation technologies[2][7]
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Eli Lilly & CompanyDEKA Research & Development Corp.MannKind CorporationNational Cancer Institute[2]
04
Financials
- Market cap
- $24.3B
- Total revenue
- $3.2B
- Enterprise value
- $22.2B
Beyond the preview
Go deeper on United Therapeutics Corporation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on United Therapeutics Corporation.